|
US8815951B2
(en)
*
|
1996-08-13 |
2014-08-26 |
The Regents Of The University Of California |
Inhibitors of epoxide hydrolases for the treatment of inflammation
|
|
US6150415A
(en)
*
|
1996-08-13 |
2000-11-21 |
The Regents Of The University Of California |
Epoxide hydrolase complexes and methods therewith
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
US6831099B1
(en)
*
|
1999-05-12 |
2004-12-14 |
Yale University |
Enzyme inhibition
|
|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
US6562563B1
(en)
|
1999-11-03 |
2003-05-13 |
Mitokor |
Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
WO2002082082A2
(en)
*
|
2001-04-09 |
2002-10-17 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Fluorescence polarization assay
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US6756210B2
(en)
*
|
2001-05-29 |
2004-06-29 |
The Regents Of The University Of California |
Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids
|
|
US6979733B2
(en)
*
|
2001-08-03 |
2005-12-27 |
Diversa Corporation |
Epoxide hydrolases, nucleic acids encoding them and methods of making and using them
|
|
US6943001B2
(en)
*
|
2001-08-03 |
2005-09-13 |
Diversa Corporation |
Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
|
|
US20030139469A1
(en)
*
|
2002-01-23 |
2003-07-24 |
The Regents Of The University Of California |
Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
|
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
GB0214342D0
(en)
*
|
2002-06-21 |
2002-07-31 |
Givaudan Sa |
Insect repellents
|
|
EA010267B1
(ru)
|
2002-10-07 |
2008-06-30 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
Модуляция тревоги через блокаду гидролиза анандамида
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
US20050026844A1
(en)
*
|
2003-04-03 |
2005-02-03 |
Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
|
US20050164951A1
(en)
*
|
2003-04-03 |
2005-07-28 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
|
WO2005089380A2
(en)
|
2004-03-16 |
2005-09-29 |
The Regents Of The University Of California |
Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
ES2257152B1
(es)
*
|
2004-05-31 |
2007-07-01 |
Laboratorios Almirall S.A. |
Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
|
|
JP2008517072A
(ja)
*
|
2004-10-20 |
2008-05-22 |
ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア |
可溶性エポキシド加水分解酵素の改良された阻害剤
|
|
US20060276515A1
(en)
*
|
2005-05-06 |
2006-12-07 |
Cywin Charles L |
Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same
|
|
WO2006121684A2
(en)
*
|
2005-05-06 |
2006-11-16 |
Boehringer Ingelheim International, Gmbh |
Acyl hydrazones for treating cardiovascular diseases
|
|
CA2619768A1
(en)
*
|
2005-08-19 |
2007-02-22 |
The Regents Of The University Of California |
Use of seh inhibitors as analgesics
|
|
JP2009511489A
(ja)
*
|
2005-10-07 |
2009-03-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
可溶性エポキシド加水分解酵素阻害剤として有益なｎ−置換ピリジノン又はピリミジノン化合物
|
|
MY171061A
(en)
|
2005-11-09 |
2019-09-24 |
Onyx Therapeutics Inc |
Compounds for enzyme inhibition
|
|
US8791163B2
(en)
*
|
2006-01-13 |
2014-07-29 |
Mcgill University |
Melatonin ligands having antidepressant activity as well as sleep inducing properties
|
|
US20090111791A1
(en)
*
|
2006-03-10 |
2009-04-30 |
Boehringer Ingelheim International Gmbh |
Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same
|
|
AR059826A1
(es)
*
|
2006-03-13 |
2008-04-30 |
Univ California |
Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
|
|
CA2657213C
(en)
|
2006-06-19 |
2017-01-03 |
Proteolix, Inc. |
Peptide epoxyketones for proteasome inhibition
|
|
US8263651B2
(en)
*
|
2006-12-15 |
2012-09-11 |
The Regents Of The University Of California |
Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors
|
|
CN101563088A
(zh)
*
|
2006-12-18 |
2009-10-21 |
弗·哈夫曼-拉罗切有限公司 |
可溶性环氧化物水解酶的抑制剂的新用途
|
|
US8455520B2
(en)
*
|
2007-07-17 |
2013-06-04 |
Merck Sharp & Dohme Corp. |
Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
|
|
US20110098322A1
(en)
*
|
2007-08-06 |
2011-04-28 |
The Regents Of The University Of California |
Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase
|
|
KR20170125413A
(ko)
|
2007-10-04 |
2017-11-14 |
오닉스 세라퓨틱스, 인크. |
결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
|
|
WO2009111207A1
(en)
*
|
2008-03-04 |
2009-09-11 |
Merck & Co., Inc. |
Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
|
|
EP2100598A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP2100599A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP3090737A1
(en)
|
2008-10-21 |
2016-11-09 |
Onyx Therapeutics, Inc. |
Combination therapy with peptide epoxyketones
|
|
WO2010096722A1
(en)
|
2009-02-20 |
2010-08-26 |
Takeda Pharmaceutical Company Limited |
3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
|
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
|
WO2012054093A2
(en)
|
2010-01-29 |
2012-04-26 |
The Regents Of The University Of California |
Acyl piperidine inhibitors of soluble epoxide hydrolase
|
|
EP2542238B1
(en)
|
2010-03-01 |
2015-08-12 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
|
NZ602872A
(en)
|
2010-04-07 |
2014-05-30 |
Onyx Therapeutics Inc |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
EP2389922A1
(en)
|
2010-05-25 |
2011-11-30 |
Symrise AG |
Cyclohexyl carbamate compounds as anti-ageing actives
|
|
WO2012112570A1
(en)
|
2011-02-14 |
2012-08-23 |
The Regents Of The University Of California |
SORAFENIB DERIVATIVES AS sEH INHIBITORS
|
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
|
EP2809650B1
(en)
|
2012-02-01 |
2018-04-11 |
The Regents of The University of California |
Acyl piperidine inhibitors of soluble epoxide hydrolase
|
|
WO2013138118A1
(en)
|
2012-03-14 |
2013-09-19 |
The Regents Of The University Of California |
Treatment of inflammatory disorders in non-human mammals
|
|
US20140105921A1
(en)
|
2012-07-09 |
2014-04-17 |
Onyx Therapeutics, Inc. |
Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
|
|
US10813894B2
(en)
|
2015-02-20 |
2020-10-27 |
The Regents Of The University Of California |
Methods of inhibiting pain
|
|
EP3463470A1
(en)
|
2016-05-25 |
2019-04-10 |
Johann Wolfgang Goethe-Universität Frankfurt am Main |
Treatment and diagnosis of non-proliferative diabetic retinopathy
|
|
WO2020074549A1
(en)
|
2018-10-10 |
2020-04-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
|
|
CN113302298B
(zh)
|
2018-11-09 |
2025-02-25 |
银杏生物制品公司 |
罗汉果甙的生物合成
|